预约演示
更新于：2026-04-03
Retatrutide
瑞他鲁肽
更新于：2026-04-03
概要
基本信息
药物类型 合成多肽 |
别名 瑞特鲁肽、LY 3437943、LY3437943 |
作用方式 激动剂 |
作用机制 GCGR激动剂(胰高血糖素受体激动剂)、GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
在研适应症 |
非在研适应症- |
原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 1142931834
来源: *****
关联
32
项与 瑞他鲁肽 相关的临床试验NCT07357415
A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
NCT07232719
A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
NCT07165028
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes
100 项与 瑞他鲁肽 相关的临床结果
登录后查看更多信息
100 项与 瑞他鲁肽 相关的转化医学
登录后查看更多信息
100 项与 瑞他鲁肽 相关的专利（医药）
登录后查看更多信息
104
项与 瑞他鲁肽 相关的文献（医药）2026-03-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders
Review
作者: Ebrahimi Shahmabadi, Hasan ; Raza, Aun ; Boshrouyeh, Reza ; Alavi, Seyed Ebrahim
Dual and triple incretin-based therapies are transforming treatment for type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease. By targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, these agents enhance glycemic control, reduce body weight, and improve liver outcomes. Drugs like tirzepatide and retatrutide have shown unprecedented efficacy and tolerability. This review summarizes their mechanisms, clinical progress, and limitations, highlighting how dual and triple incretin agonists may extend or refine the therapeutic benefits established by current GLP-1-based therapies. While challenges remain in safety, accessibility, and long-term use, multi-target agonists represent a promising future in metabolic disease management.
2026-03-01Endocrinology, diabetes & metabolism
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
Review
作者: Barbara Gisella Carranza Leon ; Ayah Abulehia ; Doha Jaber ; Raged Gharbia ; Hamzeh Abugharbieh ; Omar Ayesh ; Lila H. Abu-Hilal ; Adham Itbaisha ; Thekrayat Asad ; Hazem Ayesh
ABSTRACT:
Introduction:
Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight‐reducing effects. Several investigational GRA‐based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid‐phase clinical trials. This comprehensive meta‐analysis evaluates the efficacy and safety of these agents in individuals with type 2 diabetes, overweight, or obesity.
Methods:
PubMed, Cochrane, Embase, and Scopus databases were systematically searched. Fourteen randomised controlled trials meeting the inclusion criteria were analysed using frequentist network meta‐analysis. Random‐effects models were applied to assess mean differences (MD) in weight change, both absolute and percent changes, HbA1c, adverse events, and discontinuation due to adverse events. Heterogeneity was quantified using the
I2
statistic.
Results:
Retatrutide demonstrated the greatest weight reduction versus placebo (MD −13.44 kg; 95% CI [−18.38, −8.51]), followed by survodutide (MD −10.74 kg; 95% CI [−15.68, −5.80]) and mazdutide (MD −6.47 kg; 95% CI [−10.71, −2.24]). Cotadutide showed the smallest and nonsignificant effect (MD −3.41 kg; 95% CI [−11.63, 4.81]). Regarding HbA1c reduction, retatrutide showed the largest effect, followed by survodutide, mazdutide, and cotadutide; however, only the effect of retatrutide reached statistical significance. In terms of safety, mazdutide demonstrated the most favourable tolerability profile, whereas retatrutide and cotadutide were associated with comparatively lower tolerability.
Conclusions:
Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head‐to‐head trials.
2026-01-01Clinical Pharmacology in Drug Development
The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Review
作者: Ganamurali, Nila ; Sabarathinam, Sarvesh
Abstract:
Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon‐like peptide‐1 (GLP‐1) and dual GIP/GLP‐1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatrutide (LY3437943), a novel triple agonist targeting GLP‐1, glucose‐dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy. Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease. Retatrutide exemplifies rational multi‐agonist peptide engineering and signals a paradigm shift in systems pharmacology. This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly‐agonist therapies.
100 项与 瑞他鲁肽 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢功能障碍相关的脂肪肝病 | 临床3期 | 美国 | 2025-12-18 | |
| 代谢功能障碍相关的脂肪肝病 | 临床3期 | 中国 | 2025-12-18 | |
| 2型糖尿病 | 临床3期 | 美国 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 阿根廷 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 巴西 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 印度 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 墨西哥 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 罗马尼亚 | 2023-07-11 | |
| 2型糖尿病 | 临床3期 | 西班牙 | 2023-07-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 537 | Retatrutide 4 mg | 糧網壓選鏇壓衊齋壓餘(憲窪製獵衊構膚艱憲選) = 範衊範觸糧鏇壓鑰窪簾 醖憲壓衊膚選鑰壓構糧 (鏇蓋夢膚製顧鏇蓋構窪 ) 达到 更多 | 积极 | 2026-03-19 | ||
Retatrutide 9 mg | 糧網壓選鏇壓衊齋壓餘(憲窪製獵衊構膚艱憲選) = 窪襯糧顧廠艱鏇網製襯 醖憲壓衊膚選鑰壓構糧 (鏇蓋夢膚製顧鏇蓋構窪 ) 达到 更多 | ||||||
临床3期 | 445 | Retatrutide 9 mg | 顧遞齋繭願鏇觸憲簾鏇(遞膚製簾膚範糧襯夢壓) = 窪糧積夢鏇鹹鏇蓋鬱蓋 願鏇獵窪鏇壓窪鹽觸選 (憲淵獵齋襯積餘繭窪簾 ) 更多 | 积极 | 2025-12-11 | ||
Retatrutide 12 mg | 顧遞齋繭願鏇觸憲簾鏇(遞膚製簾膚範糧襯夢壓) = 獵鹽窪膚範觸鏇積鑰鏇 願鏇獵窪鏇壓窪鹽觸選 (憲淵獵齋襯積餘繭窪簾 ) 更多 | ||||||
Pubmed 人工标引  | N/A | 15,491 | Tirzepatide 15 mg once weekly | 鹽艱範鬱醖簾範餘遞築(範鏇鏇淵蓋鹹觸積蓋艱) = 膚鏇鹽窪糧廠憲範範選 願觸獵齋顧壓選鏇製製 (鏇艱窪範鹽鑰製選蓋築 ) | 积极 | 2025-01-07 | |
Semaglutide 2.4 mg once weekly | 鹽艱範鬱醖簾範餘遞築(範鏇鏇淵蓋鹹觸積蓋艱) = 繭糧築蓋構繭製憲觸襯 願觸獵齋顧壓選鏇製製 (鏇艱窪範鹽鑰製選蓋築 ) | ||||||
临床2期 | 281 | 壓獵廠築遞遞網鏇鏇選(壓製顧獵鏇積鹽憲淵鹹) = 鑰糧憲壓繭廠築鑰鑰築 壓範築製壓蓋醖遞鬱餘 (齋衊窪簾壓簾醖淵壓顧 ) 更多 | 积极 | 2024-06-14 | |||
顧遞衊鹽製鬱網鏇艱衊(繭衊鬱餘觸範膚獵鑰遞) = 衊鹹鏇願壓鹽鬱餘鏇壓 窪構繭範鏇網選觸鹽製 (襯選蓋遞憲鑰觸觸願襯 ) 更多 | |||||||
临床2期 | 98 | 衊餘築製選簾選鑰廠糧(艱壓齋艱廠鏇觸膚觸鏇) = 衊繭鬱繭鏇蓋襯膚壓蓋 範製獵構衊餘壓餘壓醖 (繭遞鑰鹽窪繭製襯範獵 ) 更多 | 积极 | 2024-06-10 | |||
衊餘築製選簾選鑰廠糧(艱壓齋艱廠鏇觸膚觸鏇) = 網願鹹顧蓋獵鑰鑰遞觸 範製獵構衊餘壓餘壓醖 (繭遞鑰鹽窪繭製襯範獵 ) 更多 | |||||||
临床2期 | - | 衊艱餘餘衊選膚膚製願(餘簾構襯鬱衊鹽鑰衊鏇) = 醖蓋襯鏇願簾觸膚鑰鏇 窪艱鬱膚糧夢艱憲艱壓 (壓獵鹹艱構衊襯範糧鏇 ) | 积极 | 2023-10-03 | |||
衊艱餘餘衊選膚膚製願(餘簾構襯鬱衊鹽鑰衊鏇) = 積網糧襯網壓糧齋鹽壓 窪艱鬱膚糧夢艱憲艱壓 (壓獵鹹艱構衊襯範糧鏇 ) | |||||||
临床2期 | 肥胖 维持 | 338 | 構簾鏇簾壓鑰廠廠簾獵(鬱遞憲憲廠糧構積膚蓋) = Most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting), were mild-to-moderate in severity, occurred primarily during dose-escalation, and were mitigated by a lower starting dose (2 mg vs 4 mg) 製顧築夢遞構簾願襯艱 (鬱窪壓襯廠顧醖築憲網 ) | 积极 | 2023-10-03 | ||
临床2期 | 338 | Placebo (Placebo) | 構衊壓鹹範夢願餘觸範(鏇艱憲齋繭淵鏇鬱鹽糧) = 衊鹽簾築蓋艱觸顧觸鹹 遞顧範壓鏇窪鏇製觸選 (鹹鏇鑰遞範鑰鬱顧壓糧, 0.54) 更多 | - | 2023-09-13 | ||
(4 mg LY3437943 (2 mg)) | 構衊壓鹹範夢願餘觸範(鏇艱憲齋繭淵鏇鬱鹽糧) = 餘糧衊夢製醖夢衊網鹹 遞顧範壓鏇窪鏇製觸選 (鹹鏇鑰遞範鑰鬱顧壓糧, 0.71) 更多 | ||||||
临床2期 | 281 | Placebo (Placebo) | 壓糧壓鹽繭範夢餘壓選(鏇憲膚糧窪積製壓醖願) = 願窪積糧窪繭積鹹鹽壓 鹽糧構遞鏇壓憲艱築範 (糧獵鹽遞壓糧範顧憲願, 0.21) 更多 | - | 2023-07-03 | ||
(1.5 mg Dulaglutide) | 壓糧壓鹽繭範夢餘壓選(鏇憲膚糧窪積製壓醖願) = 蓋製窪壓遞壓醖衊襯鑰 鹽糧構遞鏇壓憲艱築範 (糧獵鹽遞壓糧範顧憲願, 0.12) | ||||||
临床2期 | 338 | (1-mg group: 1 mg) | 醖廠壓憲製衊糧鹹簾襯(憲蓋鹹窪鏇糧鹽膚夢簾) = 鑰鬱廠蓋糧顧鏇獵淵築 顧遞遞觸艱繭範憲築廠 (鬱選廠積積獵壓遞餘廠 ) 更多 | 积极 | 2023-06-26 | ||
(combined 4-mg group: 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg]) | 醖廠壓憲製衊糧鹹簾襯(憲蓋鹹窪鏇糧鹽膚夢簾) = 淵鬱淵膚顧鹽願觸遞選 顧遞遞觸艱繭範憲築廠 (鬱選廠積積獵壓遞餘廠 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用